The FDA has issued a CRL to Biohaven regarding the NDA for troriluzole for the treatment of adults with spinocerebellar ataxia.

The global Friedreich’s ataxia market is experiencing notable growth, fueled by advancements in genetic research, enhanced diagnostic technologies, and increased awareness of this rare ...

After the FDA rejected its spinocerebellar ataxia treatment, Biohaven missed out on a $150 million payment from Oberland Capital. Now the company is reshuffling its pipeline to stay alive.

The troriluzole clinical development program encompassed the first industry clinical trials to generate data showing therapeutic potential in patients with spinocerebellar ataxia (SCA), a rare genetic ...

In October, the U.S. Food and Drug Administration (FDA) for the first time ever issued an Emergency Use Authorization (EUA) ...

Biohaven is proposing troriluzole for the treatment of spinocerebellar ataxia, a group of rare, genetic diseases that lead to the progressive loss of control over movement.

Biohaven (BHVN) stock plunges as the FDA declines to approve its lead drug Vyglxia (troriluzole) targeted at spinocerebellar ataxia. Read more here.

(Nasdaq: QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient’s own biology for the treatment of rare diseases, today announced the positive outcome of its ...

A green light would have made Vyglxia the first and only FDA-approved treatment for spinocerebellar ataxia, a life-threatening neurodegenerative disease characterized by progressive loss of voluntary ...